Ranchi News Desk

CD BioSciences Launches Chemical Mutagenesis Services in C. elegans to Support the Establishment of Animal Models for Diseases

 Breaking News
  • No posts were found

CD BioSciences Launches Chemical Mutagenesis Services in C. elegans to Support the Establishment of Animal Models for Diseases

January 05
21:25 2023
CD BioSciences announced the release of its chemical mutagenesis services in C.elegans to support the establishment of animal models for disease.

New York, USA – January 5, 2023 – CD BioSciences is a professional provider of C. elegans model services including C. elegans genome editing, the construction of C. elegans stress response model, aging research, drug screening, and C. elegans biology among others. With rich experience in the fields of C. elegans research and advanced instruments, CD BioSciences is capable to accelerate and improve the drug screening process with novel products and technologies. Recently, CD BioSciences announced the release of its chemical mutagenesis services in C.elegans to support the establishment of animal models for disease.

CD BioSciences provides a rapid and scalable platform for high-throughput screening to identify mutants with two widely used chemical mutagenesis methods. C. elegans growth, mutagenesis procedures, screening, and mutation recovery all in 96-well microtiter plates. Currently available services from CD BioSciences include a C. elegans EMS mutagenesis service with ethyl methanesulfonate (EMS), an alkylating agent whose mutagenicity was first demonstrated in 1959 using the T4 virus system. With relatively low toxicity and relatively good efficiency, EMS is the most commonly used chemical mutagen for mutagenizing the genome of clostridium difficile.

Currently, available services from CD BioSciences include C. elegans EMS mutagenesis services, which typically begin with phenotypic screening and end with identification of mutation sites, enhancers or suppressors can also be used to screen for mutations that enhance or suppress a particular phenotype in a known genetic background. CD BioSciences is committed to finding solutions that improve research outcomes and dramatically increase the speed of success. EMS mutagenesis is one of a comprehensive range of chemical mutagenesis services.

C.elegans ENU mutagenesis service creates modified DNA bases by transferring their ethyl moieties to nitrogen or oxygen on any of the four nucleotides, which then impedes correct replication, mainly used in cell phenotype studies, and the identification of novel alleles in embryonic organogenesis.

“We are committed to finding solutions that improve research outcomes and dramatically increase the speed of success,” said Marcia Brady, the marketing director of CD BioSciences. She also added, “Based on a high-throughput genetic screening platform, we can help you induce and screen for phenotype-specific mutations in caenorhabditis elegans with a fast, scalable procedure.”

About CD BioSciences

CD BioSciences is dedicated to helping our clients to achieve effective and successful research. We aim to provide our customers with high-quality data delivery, in-depth scientific and technical support. Our professional team is capable to offer comprehensive and systematic services that contribute to the better use of C. elegans for researchers.

Media Contact
Company Name: CD BioSciences
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-372-1052
Country: United States
Website: https://www.elegansmodel.com

Related Articles